Fadini Gian Paolo, Ciardullo Stefano, Perseghin Gianluca, Giordano Carla, Maddaloni Ernesto, Buzzetti Raffaella, Ghiani Mariangela, Avogaro Angelo
Department of Medicine, Unit of Metabolic Diseases, University of Padova, via Giustiniani 2, 35128, Padua, Italy.
Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy.
Diabetes Ther. 2025 Jun;16(6):1241-1254. doi: 10.1007/s13300-025-01729-4. Epub 2025 Mar 28.
Diabetes management often involves complex insulin regimens, posing significant challenges for patients and healthcare systems. Weekly basal insulin formulations aim to simplify treatment, reduce injection frequency, and improve adherence and quality of life. This study explored the beliefs, preferences and attitudes of patients, physicians and payers regarding current basal insulin therapy and weekly insulin formulations.
An online survey with structured questionnaires was developed for multiple stakeholders: patients with type 1 or type 2 diabetes, physicians and payers. Participants provided self-reported insights into basal insulin therapy and perceptions of weekly formulations. Results are presented in a descriptive non-analytical way.
A total of 1094 patients, 468 physicians and 100 payers participated. Patients reported moderate satisfaction with current insulin therapy, with lower satisfaction in type 2 diabetes (T2D). The major burdens identified were daily injections and fear of hypoglycaemia, with weekly insulin seen as a promising alternative. Physicians prioritized glycaemic control goals, while patients emphasized independence and quality of life. Payers valued adherence and hypoglycaemia avoidance but raised concerns about costs and education needs.
According to this multi-stakeholder survey, weekly basal insulin offers a promising approach to reduce treatment burden and improve adherence and quality of life. Addressing concerns about safety, efficacy and cost will be critical to its successful adoption in clinical practice.
糖尿病管理通常涉及复杂的胰岛素治疗方案，给患者和医疗系统带来重大挑战。每周一次的基础胰岛素制剂旨在简化治疗、减少注射频率，并提高依从性和生活质量。本研究探讨了患者、医生和支付方对当前基础胰岛素治疗和每周一次胰岛素制剂的看法、偏好和态度。
为多个利益相关者（1型或2型糖尿病患者、医生和支付方）设计了一份带有结构化问卷的在线调查。参与者对基础胰岛素治疗及对每周一次制剂的看法提供了自我报告的见解。结果以描述性而非分析性的方式呈现。
共有1094名患者、468名医生和100名支付方参与。患者对当前胰岛素治疗的满意度为中等，2型糖尿病（T2D）患者的满意度较低。确定的主要负担是每日注射和对低血糖的恐惧，每周一次的胰岛素被视为一种有前景的替代方案。医生将血糖控制目标列为优先事项，而患者则强调独立性和生活质量。支付方重视依从性和避免低血糖，但对成本和教育需求表示担忧。
根据这项多利益相关者调查，每周一次的基础胰岛素为减轻治疗负担、提高依从性和生活质量提供了一种有前景的方法。解决对安全性、有效性和成本的担忧对于其在临床实践中的成功应用至关重要。
